Equity Overview
Price & Market Data
Price: $1.37
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $8,258,373
Volume: 0
Performance Metrics
1 Week: 5.38%
1 Month: -7.43%
3 Months: -49.26%
6 Months: 96.98%
1 Year: -11.04%
YTD: 113.7%
Company Details
Employees: 8
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on developing and commercializing new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which is in Phase 1 clinical trials to address certain types of neuropathic pain. It also intends to develop CT2000 as a topical agent for the relief of eye pain; and CT2000 for the potential treatment of both acute and chronic eye pain. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.